Chemistry:Pegzilarginase
Pegzilarginase, sold under the brand name Loargys, is a medication used for the treatment of hyperargininemia.[1][2]
The most common side effects include allergic reactions.[1]
Pegzilarginase was approved for medical use in the European Union in December 2023.[2]
Pegzilarginase was approved for medical use in the United States in February 2026.[3]
Medical uses
Pegzilarginase is indicated for the treatment of arginase 1 deficiency, also known as hyperargininemia.[1][2]
Society and culture
Legal status
In October 2023, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Loargys, intended for the treatment of hyperargininemia.[1] The applicant for this medicinal product is Immedica Pharma AB.[1] Pegzilarginase was approved for medical use in the European Union in December 2023.[2]
Brand names
Pegzilarginase is the international nonproprietary name.[4]
Pegzilarginase is sold under the brand name Loargys.[1]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Cite error: Invalid
<ref>tag; no text was provided for refs namedLoargys EPAR - ↑ 2.0 2.1 2.2 2.3 Cite error: Invalid
<ref>tag; no text was provided for refs namedLoargys Product information - ↑ "U.S. FDA has granted accelerated approval of Loargys® (pegzilarginase-nbln) for the treatment of hyperargininemia in patients 2 years and older with arginase 1 deficiency (ARG1-D) | Immedica". https://www.immedica.com/en/press/us-fda-has-granted-accelerated-approval-loargysr-pegzilarginase-nbln-treatment.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79". WHO Drug Information 32 (1). 2018.
External links
- "Pegzilarginase (Code C125143)". 27 November 2023. https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C125143.
 |  |
